Novartis plots new course for Sandoz

During his first full year earnings readout as CEO of Novartis AG (NYSE:NVS; SIX:NOVN), Vasant Narasimhan said the company intends to turn Sandoz into "an autonomous entity over the next 18 months that is able to compete as an independent unit within Novartis."